Combatting multidrug resistant bacteria in the clinic - Dr Ben Mullish - Part 1 of 2 Imperial College London youtu.be/5P3qBSOA2vU?...

Combatting multidrug resistant bacteria in the clinic - Dr Ben Mullish - Part 1 of 2

YouTube video by Imperial College London

youtu.be

Pleased to see out this paper in #Gut on behalf of the @britsocgastro.bsky.social Gut Microbiota for Health panel - taking stock of where we have come in the last decade in translating gut #microbiome research: gut.bmj.com/content/earl... @imperialmdr.bsky.social

🆕The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus www.thelancet.com/journals/lan... #LiverSky #MedSky

The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus

Metabolic dysfunction-associated steatohepatitis (MASH), a potentially progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), increases risk of fibrosis progression, cir...

thelancet.com

ICYMI: New online! Defining ‘gut health’: a leap forward, but still some road to travel

New online! Defining ‘gut health’: a leap forward, but still some road to travel

Donor screening for #FMT gets ever more complicated, but is there rationale for this? Great to play a part in this critical appraisal and international Delphi process on this issue, now out in #Gut: gut.bmj.com/content/earl... @imperialmdr.bsky.social #GastroSky #IDSky #MicrobiomeSky

New research @eClinicalMed - A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities www.thelancet.com/journals/ecl... #GastroSky #MedSky #IBDSky

A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities

Treatment efficacy in similar WH and SA IBD patients recruited to the UK IBD BioResource is unaffected by ethnicity but patients from SA ethnic backgrounds are at increased risk of developing pancreat...

thelancet.com

Great to see out this study from Sharmili Balarajah and Laura Martinez-Gili @imperialmdr.bsky.social, working with the #IBD @nihrbioresource.bsky.social, comparing outcomes with #IBD therapies in White and South Asian patients, now in @eclinicalmed.bsky.social: www.sciencedirect.com/science/arti...

A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities

While ethnic differences in IBD phenotype are recognised, the comparative efficacy and safety of common IBD therapies across ethnically diverse popula…

sciencedirect.com

Very pleased to see this practical guide to #nutrition in #cirrhosis out in #FrontlineGastroenterology: fg.bmj.com/content/earl.... Thanks to Luke Tyson for leading the group! #liversky

Honoured to speak on #FMT #LBPs at the #EHMSG meeting today in session with Nicolas Benech and Jens Walter. Thanks to Gianluca Ianiro for organising, and for even getting a @nobelprize.bsky.social winner for Physics to speak to us, Giorgio Parisi! @imperialmdr.bsky.social #microbiomeclinicians

www.sciencedirect.com/science/arti... - we used an AMS approach to operationalise & formalise a structured approach to FMT @imperialcollegeldn.bsky.social @imperialnhs.bsky.social

Operational considerations for the running of an NHS faecal microbiota transplant (FMT) service

sciencedirect.com

Out now from us in @thejhi.bsky.social - operational considerations in running an #NHS #FMT service: www.sciencedirect.com/science/arti... @imperialmdr.bsky.social @imperialbrc.bsky.social #GastroSky #MicroSky #IDSky

Operational considerations for the running of an NHS faecal microbiota transplant (FMT) service

sciencedirect.com

Very pleased to see this out in @cmijournal.bsky.social - what non-antimicrobial options are there for recurrent #UTI, and what might be the role for #FMT? www.clinicalmicrobiologyandinfection.com/article/S119... @rohmaghani.bsky.social @imperialmdr.bsky.social @imperialbrc.bsky.social #MicroSky

We’ve also written a Behind the Paper blog post to accompany our article, which you can find here: go.nature.com/401ctsa

Antibiotics fuel the rise of vancomycin-resistant enterococci intestinal colonisation by remodelling the metabolic landscape of the gut microbiome

Antibiotics save lives- but also reshape the gut microbiome, unintentionally promoting VRE colonisation. This study reveals how antibiotic-driven metabolic shifts promote VRE expansion and highlights ...

go.nature.com

Great to see this work from Shiv Radhakrishnan and colleagues out in #GutMicrobes - using network analysis to explore #microbiome #metabolome interactions in an #IBD inception cohort: doi.org/10.1080/1949... @imperialmdr.bsky.social @imperialhepatology.bsky.social #IBDSky #GISky

So excited to share a new paper from my lab just published in Nature Communications! We showed that vancomycin-resistant enterococci (VRE) occupied distinct intestinal niches in the antibiotic-treated intestine. doi.org/10.1038/s414... Amazing work by first author Olivia King and colleagues!

Vancomycin-resistant enterococci utilise antibiotic-enriched nutrients for intestinal colonisation - Nature Communications

Here, the authors show that vancomycin-resistant enterococci grow in the antibiotic-treated gut microbiome by utilising enriched nutrients in the presence of reduced concentrations of inhibitory micro...

doi.org

Vancomycin-resistant 𝙀𝙣𝙩𝙚𝙧𝙤𝙘𝙤𝙘𝙘𝙪𝙨 𝙛𝙖𝙚𝙘𝙞𝙪𝙢 (VRE) thrives in the antibiotic-perturbed gut VRE gobbles up enriched sugars and amino acids, and loss of short-chain fatty acids (acetate, propionate, butyrate) eliminates natural growth brakes Therapeutic angle: Prebiotic SCFA mixtures block VRE growth!

Vancomycin-resistant enterococci utilise antibiotic-enriched nutrients for intestinal colonisation - Nature Communications

Here, the authors show that vancomycin-resistant enterococci grow in the antibiotic-treated gut microbiome by utilising enriched nutrients in the presence of reduced concentrations of inhibitory micro...

nature.com

A great privilege to work with @julieakmcdonald.bsky.social lab on this new paper, now out in @natureportfolio.nature.com Communications - how #antibiotic-related changes in gut #nutrients and #metabolites promote #VRE colonisation: doi.org/10.1038/s414... @imperialmdr.bsky.social

Honoured to to be part of this Future of Hepatology session at @easlnews.bsky.social #EASL2025, discussing the promise of #microbiome related therapies in #PSC #cholestatic liver disease - where have we come since the original #FMT #PSC pilot study by @DrAllegrettiIBD? doi.org/10.14309/ajg...

Delighted to welcome Manchester Royal Infirmary onto the #MAST trial as our seventh site! Pleased to be able to expand our coverage for this important trial of #GutMicrobiome manipulation with #IMT #FMT before #HCT; find out more here: www.imperial.ac.uk/metabolism-d... @imperialmdr.bsky.social

MAST study

The Imperial MAST study: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) study.

imperial.ac.uk

Want to know more about why we are looking at the #GutMicrobiome #IMT #HCT as therapy? Find out even more here: youtu.be/zDd1qdVCa6A?...

The #MAST trial is pushing forward, investigating the impact of #IMT #FMT prior to #HCT in seven UK centres #HaemSky #MicrobiomeSky #GastroSky @imperialmdr.bsky.social @bloodcanceruk.bsky.social ruk.bsky.social @anthonynolan.bsky.social. Find out more from our poster or our website: rb.gy/myizsb

The relationships between MASLD, extrahepatic multimorbidity and all-cause mortality in UK Biobank cohort https://www.medrxiv.org/content/10.1101/2025.03.09.25323328v1

A great first day at the #BSG #GutMicrobiome event, covering everything from early life @halllab.bsky.social, to #liver @debbieshawcross.bsky.social, to #cancer @jameskinross.bsky.social, and culminating in a tour de force on #IBD and the #microbiome in clinical practice from Prof Harry Sokol

MAST is moving onwards and upwards and now up to 18 recruited patients. We push on, hoping to see how gut #microbiome manipulation with #IMT #FMT can help our patients with #BloodCancer #HCT @bloodcanceruk.bsky.social @anthonynolan.bsky.social

Pleased that #FARGO - a randomised, multicentre, placebo-controlled phase IIa trial of #FMT to treat #PSC - is running and recruiting. Have a look at the protocol paper out now in #BMJOpen: doi.org/10.1136/bmjo... @pscsupport.bsky.social @cholestasisdoc.bsky.social

Great that the #MAST trial is moving ahead, and really hoping that this shows the #microbiome as a route to give new treatment prospects to #HCT #BloodCancer patients @bloodcanceruk.bsky.social @cancerresearchuk.org

MAST Study@mast-study.bsky.social · 2y ago

Now out - protocol paper for the #MAST trial, exploring #IMT #FMT to #prehabilitate the #GutMicrobiome in #BloodCancer patients receiving #HCT, now in #BMJOpen: doi.org/10.1136/bmjo... . Grateful to #MRC #DPFS for funding and #EnteroBiotix as project partners #HaemSky #MicrobiomeSky #GastroSky

Great work by Nabil Quraishi, Palak Trivedi and many others - unravelling the positive impact of #vancomycin in #PSC #IBD by altering interactions between the host, #microbiome, and #metabolome. Now in #JCC: academic.oup.com/ecco-jcc/adv... #GastroSky

Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures

AbstractBackground. We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV

academic.oup.com

Great to work with the lab of @julieakmcdonald.bsky.social and see this preprint out on @biorxivpreprint.bsky.social, looking at how nutrient availability and microbial #metabolites impact #VRE colonisation in the #antibiotic treated gut: www.biorxiv.org/content/10.1... #MicroSky #GastroSky

Julie A. K. McDonald@julieakmcdonald.bsky.social · 2y ago

I’m excited to share a new preprint from our lab! We showed that vancomycin-resistant Enterococcus (VRE) colonise antibiotic-treated intestines by occupying distinct nutrient- and metabolite-defined intestinal niches. www.biorxiv.org/content/10.1...

Great work by Sharmili Balarajah with #ImperialMDR colleagues and the @nihr.bsky.social #IBD Bioresource team, now in press in #JCC - exploring differences in #IBD phenotypes and treatment approaches between White and South Asian patients in the UK: academic.oup.com/ecco-jcc/adv...

Diverse phenotypes, consistent treatment: a study of 30,997 South Asian and White IBD patients using the UK IBD BioResource

AbstractObjective. To evaluate South Asian (SA) and White (WH) inflammatory bowel disease (IBD) phenotypes, and to explore treatment approach variations be

academic.oup.com